Actinium Pharmaceuticals Aktie

Actinium Pharmaceuticals ab 0 Euro bei Finanzen invest ordern (zzgl. Spreads)

WKN DE: A110R5 / ISIN: US00507W1071

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
23.10.2026 16:46:22

Actinium Advances HER3-Targeted Radiotherapy In Phase 1 Prostate Cancer Study

(RTTNews) - Actinium Pharmaceuticals (ATNM) announced that its first-in-human Phase 1 study of ATNM-400, an investigational HER3-targeted radiotherapy, will be featured at the ESMO 2026 Congress in Madrid, Spain, from October 23-27.

The study evaluates ATNM-400 in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with and without prior PSMA-directed therapy. The therapy combines a HER3-targeting antibody with the alpha-emitting isotope Actinium-225, offering an approach distinct from PSMA-targeted treatments.

The multicenter, open-label study assesses safety, tolerability, dosimetry, pharmacokinetics and antitumor activity to determine a recommended Phase 2 dose. Patients undergo Zirconium-89-labeled imaging to assess tumor uptake before therapeutic treatment. The ESMO presentation is listed as an ePoster under "Trial in Progress."

Currently, ATNM is trading at $1.54, down 3.78%.

Nachrichten zu Actinium Pharmaceuticals Inc

mehr Nachrichten
Keine Nachrichten verfügbar.

Analysen zu Actinium Pharmaceuticals Inc

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!